Physician profile
Patrick K Timms
NPI 1861455099
$14,877.80
in general payments reported to CMS, 2019-2025
36 companies · $3,064 in 2025
The $3,064 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,494 · 2020: $1,292 · 2021: $1,728 · 2022: $1,798 · 2023: $2,478 · 2024: $3,024 · 2025: $3,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,467 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,466.77 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,416.94 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,730.81 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,029.35 | 2019-2025 | |
| Janssen Biotech, INC. | $964.17 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $922.31 | 2021-2025 | Saphnelo |
| Pfizer INC. | $745.99 | 2019-2025 | |
| Ucb, INC. | $670.61 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $459.24 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $400.98 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $378.12 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $300.69 | 2019-2025 | Orencia |
| Genzyme Corporation | $272.63 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.18 | 2020-2025 | Ofev |
| Genentech USA, INC. | $181.51 | 2019-2022 | |
| Celgene Corporation | $164.82 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $157.27 | 2023-2024 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $123.34 | 2019 | |
| Fresenius Kabi USA, LLC | $84.85 | 2023-2024 | Idacio |
| Radius Health, INC. | $75.80 | 2019-2023 | Tymlos |
| Sanofi-Aventis U.S. LLC | $58.75 | 2020 | |
| Eisai INC. | $55.87 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $52.98 | 2023-2025 | Purified Cortrophin Gel |
| Genentech, INC. | $49.95 | 2021 | |
| Alexion Pharmaceuticals, INC. | $46.14 | 2019 | |
| Hikma Pharmaceuticals USA | $44.20 | 2019-2020 | |
| Mylan Institutional INC. | $43.22 | 2023 | |
| Aurinia Pharma U.S., INC. | $36.30 | 2021-2024 | Lupkynis |
| Bioventus LLC | $32.91 | 2022-2025 | Gelsyn-3 |
| Sebela Pharmaceuticals INC. | $27.94 | 2019 | |
| Mallinckrodt Enterprises LLC | $19.60 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.40 | 2022 | |
| Pacira Therapeutics, INC. | $19.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.82 | 2023 | |
| Novo Nordisk INC | $15.14 | 2024 | Wegovy |
| Merck Sharp & Dohme LLC | $13.59 | 2019 | |
| Dynasplint Systems INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Timms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.